Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NMT1 | P30419 | 5/20 | 0.45 |
| ▸ | NMT2 | O60551 | 4/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943792 | 1.00 | GSR (0.53) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL29465874 | 1.00 | GSR (0.53) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL29592035 | 0.97 | GSR (0.50) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL30581338 | 0.97 | GSR (0.50) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL29630424 | 0.97 | GSR (0.50) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL29943324 | 0.97 | GSR (0.50) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL1923416 | 0.97 | GSR (0.56) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL28264447 | 0.97 | GSR (0.56) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL10522441 | 0.95 | GSR (0.51) | GSRDPP8DPP9DPP7FOLH1 | |
| SCHEMBL10522423 | 0.95 | GSR (0.51) | GSRDPP8DPP9DPP7FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403419-A1 | SERINE DERIVATIVE COMPOUND FOR THE PREVENTION OR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | ASTROGEN CO., LTD. (KR) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403419-A1 | SERINE DERIVATIVE COMPOUND FOR THE PREVENTION OR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | LRRK2, NLN, MAPT | GSR 187/4885DPP8 3353/4885DPP9 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.